Indian Court Restrains Cipla From Exporting Generic Tarceva
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said
You may also be interested in...
Cipla Questions Patentability Of Roche’s Tarceva In Ongoing Dispute
MUMBAI - The long drawn patent fight in India between Swiss drug giant Roche and Indian generics company Cipla over lung cancer drug Tarceva (erlotinib) is poised for an interesting turn
Cipla Questions Patentability Of Roche’s Tarceva In Ongoing Dispute
MUMBAI - The long drawn patent fight in India between Swiss drug giant Roche and Indian generics company Cipla over lung cancer drug Tarceva (erlotinib) is poised for an interesting turn
Patent Registration-Marketing Linkage Row in India
NEW DELHI - With India's drug quality regulator announcing its intention to link giving marketing approval for a drug to its patent status, domestic pharmaceutical companies are up in arms against the move, while multinational firms have welcomed it